/
NPCE
$16.53+$0.06 (+0.36%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$561.5M
34M shares
52-week range
$7.56 – $19.60
74% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
1.28%
Moderate
Price (6 mo)
Loading chart…
Change$-7.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $37.0M | $41.1M | $45.2M | $45.5M | $65.4M | $79.9M | $100.0M |
| Cost of revenue | $10.5M | $10.9M | $11.7M | $13.0M | $17.3M | $20.8M | $22.8M |
| Gross profit | $26.5M | $30.3M | $33.4M | $32.5M | $48.1M | $59.1M | $77.2M |
| Gross margin | 71.6% | 73.6% | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% |
| R&D | $18.3M | $15.7M | $18.2M | $21.9M | $20.8M | $23.7M | $27.9M |
| Operating income | −$22.0M | −$13.1M | −$23.7M | −$40.8M | −$27.2M | −$21.7M | −$16.3M |
| EBITDA | −$20.1M | −$12.5M | −$28.4M | −$36.6M | −$22.8M | −$16.6M | −$12.1M |
| Net income | −$30.0M | −$24.3M | −$36.1M | −$47.1M | −$33.0M | −$27.1M | −$21.5M |
| Net margin | -81.1% | -59.0% | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
| EPS (diluted) | -2.70 | -2.17 | -2.17 | -1.91 | -1.27 | -0.93 | -0.66 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $100M | $-0.64 | $-0.82–$-0.49 | 6 |
| 2027 | $123M | $-0.34 | $-0.77–$0.11 | 5 |
| 2028 | $153M | $-0.19 | $-1.07–$0.43 | 5 |
| 2029 | $187M | $0.39 | $0.38–$0.40 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Neuropace, Inc. Common Stock
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
www.neuropace.com- Employees
- 220
- IPO / List date
- Apr 22, 2021
- HQ
- MOUNTAIN VIEW, CA
Held by traders on TradeandTell
No one on the platform currently holds NPCE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 174,311 | $2.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NPCE yet.
